Afecta Pharmaceuticals

Afecta Pharmaceuticals

Pharmaceuticals, Irvine, California, United States, 1-10 Employees

afectapharm.com

  • twitter
  • LinkedIn

phone no Phone Number: 94********

Who is AFECTA PHARMACEUTICALS

Afecta Pharmaceuticals, Inc. is a patient-centric, physician driven pharmaceutical company focused on discovering and optimizing small molecules to treat inflammatory diseases. The compan...

Read More

map
  • Irvine, California, United States Headquarters: Irvine, California, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 5122 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AFECTA PHARMACEUTICALS

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Afecta Pharmaceuticals

Answer: Afecta Pharmaceuticals's headquarters are located at Irvine, California, United States

Answer: Afecta Pharmaceuticals's phone number is 94********

Answer: Afecta Pharmaceuticals's official website is https://afectapharm.com

Answer: Afecta Pharmaceuticals's revenue is $1 Million to $5 Million

Answer: Afecta Pharmaceuticals's SIC: 5122

Answer: Afecta Pharmaceuticals's NAICS: 561110

Answer: Afecta Pharmaceuticals has 1-10 employees

Answer: Afecta Pharmaceuticals is in Pharmaceuticals

Answer: Afecta Pharmaceuticals contact info: Phone number: 94******** Website: https://afectapharm.com

Answer: Afecta Pharmaceuticals, Inc. is a patient-centric, physician driven pharmaceutical company focused on discovering and optimizing small molecules to treat inflammatory diseases. The company has validated its proprietary Artificial Intelligence powered disease/drug targeting platform, PharmetRxTM, by discovering and optimizing SPN-810, a drug in development with Supernus Pharmaceuticals (NASDAQ: SUPN). SPN-810 has received FDA Fast Track status and is expected to enter the market in 2019 and reach $1B in revenues at peak. Afecta has now developed a new pipeline of de-risked, small molecule immune- modulating drugs with fast-to-market potential through the FDA 505(b)(2) pathway. Our current internal drug development programs focus on addressing unmet needs in dermatology using several of the drugs we have discovered

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access